항류마티스제 시장 : 약물 종류별, 투여 경로별, 유형별, 질환 유형별, 유통 채널별 - 세계 예측(2025-2030년)

The Anti-Rheumatics Market was valued at USD 91.54 billion in 2023 and is projected to grow to USD 96.56 billion in 2024, with a CAGR of 5.68%, reaching USD 134.77 billion by 2030.

The global market for anti-rheumatics is undergoing an era of notable change that calls for a deep understanding of the evolving therapeutic landscape. In recent years, stakeholders have observed unprecedented advancements in treatment modalities, driving a steady and promising growth in various segments. This report introduces a detailed analysis that not only reflects current industry metrics but also anticipates future challenges and opportunities. Over time, increasing patient demand paired with innovative research and development has encouraged market players to reevaluate conventional treatment strategies and embrace novel therapeutic approaches. The dynamic nature of the healthcare environment has fostered a spirit of collaboration and competition, leading to significant improvements in patient outcomes and enhanced product pipelines. Furthermore, evolving global policies and regulatory reforms have streamlined pathways for faster product approvals and heightened market confidence. Leveraging robust data analytics and advanced digital tools, the study presents a comprehensive view that is essential for decision-makers and industry experts. This briefing serves as a primer to understand the complexities of the anti-rheumatics market, setting the stage for a detailed exploration of key industry trends and competitive strategies.

Transformative Shifts in the Anti-Rheumatics Market Landscape

Recent years have witnessed transformative shifts that have reshaped the anti-rheumatics market, positioning it at the frontier of medical innovation and patient care. The industry has experienced a surge in advanced research methodologies, enabling the development of targeted treatments and personalized therapies. These innovations have been driven by improvements in biotechnology and a deeper understanding of the pathophysiology of rheumatic diseases. A significant shift has been observed in the regulatory framework where authorities across several regions have expedited the approval processes, resulting in quicker market access for groundbreaking therapies. Collaborative ventures and strategic partnerships have bolstered research and development, leading to a proliferation of novel agents that target specific inflammatory pathways. Additionally, there has been a pronounced focus on embracing digital health and data analytics, which has improved diagnostics and patient monitoring, ultimately enhancing therapeutic outcomes. As patients demand more effective and safer alternatives, the industry has responded rapidly by integrating state-of-the-art technologies with traditional healthcare models. This adaptive approach has not only diversified the product offerings but has also strengthened market competitiveness. Emerging trends indicate that the convergence of technology with pharmaceutical development will continue to be a critical determinant of success in the anti-rheumatics market.

In-Depth Segmentation Insights Across the Anti-Rheumatics Market

A detailed segmentation analysis reveals the intricacies of the anti-rheumatics market and underscores the multi-dimensional factors driving patient care and commercial success. The market is categorized based on drug class, which includes an in-depth study of Corticosteroids, Disease Modifying Anti-rheumatics Drugs, Nonsteroidal Anti-inflammatory Drugs, and Uric Acid Drugs. Particularly noteworthy within the Disease Modifying Anti-rheumatics Drugs segment is the subdivision into Biologic DMARDs, Conventional DMARDs, and Targeted Synthetic DMARDs. Each segment within the Biologic DMARDs is further examined based on B-cell Inhibitors, Interleukin Inhibitors, T-cell Co-stimulation Modulators, and Tumor Necrosis Factor (TNF) Inhibitors, offering clarity on specific mechanisms of action and therapeutic nuances. Additionally, the analysis extends to the route of administration, capturing the dynamics of Injectable, Oral, and Topical formulations, which serve to match patient preference with clinical effectiveness. Segmentation based on product type distinguishes Over-the-Counter from Prescription-Based Drugs, thereby aligning regulatory requirements with market access. Disease type further refines the market study by considering conditions including Ankylosing Spondylitis, Bursitis, Gout, Juvenile Idiopathic Arthritis, Osteoarthritis, Osteoporosis, Polymyalgia Rheumatica, Psoriatic Arthritis, Rheumatoid Arthritis, Sjogren's Syndrome, Systemic Lupus Erythematosus, Systemic Sclerosis/Scleroderma, and Tendinitis. The final layer of segmentation examines distribution channels, highlighting Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies, which play a critical role in the accessibility and commercialization of these therapies. This comprehensive segmentation captures the detailed panorama of the market, offering stakeholders strategic insights into where future opportunities lie.

Based on Drug Class, market is studied across Corticosteroids, Disease Modifying Anti-rheumatics Drugs, Nonsteroidal Anti-inflammatory Drugs, and Uric Acid Drugs. The Disease Modifying Anti-rheumatics Drugs is further studied across Biologic DMARDs, Conventional DMARDs, and Targeted Synthetic DMARDs. The Biologic DMARDs is further studied across B-cell Inhibitors, Interleukin Inhibitors, T-cell Co-stimulation Modulators, and Tumor Necrosis Factor (TNF) Inhibitors.

Based on Route Of Administration, market is studied across Injectable, Oral, and Topical.

Based on Type, market is studied across Over-the-Counter Drugs and Prescription-Based Drugs.

Based on Disease Type, market is studied across Ankylosing Spondylitis, Bursitis, Gout, Juvenile Idiopathic Arthritis, Osteoarthritis, Osteoporosis, Polymyalgia Rheumatica, Psoriatic Arthritis, Rheumatoid Arthritis, Sjogren's Syndrome, Systemic Lupus Erythematosus, Systemic Sclerosis/Scleroderma, and Tendinitis.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.

Key Regional Insights: Navigating Global Opportunities in Anti-Rheumatics

Regional dynamics play a pivotal role in shaping the future trajectory of the anti-rheumatics market, and a nuanced understanding of geographical trends is essential. In the Americas, robust healthcare infrastructure and proactive policy measures have propelled the adoption of advanced therapies. The region presents lucrative opportunities anchored by high awareness, substantial investment in research, and progressive regulatory frameworks. Europe, Middle East & Africa is witnessing significant transformations with a focus on integrating traditional treatment models with novel therapeutic approaches. Stakeholders in this diverse region are increasingly examining the balance between cost-effectiveness and scientific innovation, paving the way for breakthrough approvals and enhanced patient outcomes. The Asia-Pacific region stands out due to its dynamic economic growth and rising middle-class populations that are driving an increased demand for quality healthcare services. Rapid urbanization, coupled with government initiatives to enhance healthcare access, has created a fertile ground for market expansion. By evaluating these regional insights, industry leaders can better strategize product positioning and market penetration, taking into account local regulatory landscapes, cultural nuances, and economic factors that influence patient care and adoption rates.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Comprehensive Analysis of Leading Companies in the Anti-Rheumatics Sector

The competitive landscape within the anti-rheumatics market is characterized by the presence of several key companies that are spearheading innovation and market expansion. Prominent entities such as AbbVie Inc., Alvotech, Amgen Inc., ANI Pharmaceuticals, Inc., and AstraZeneca PLC are at the forefront of developing and commercializing advanced therapies. Esteemed organizations like Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, and C. H. Boehringer Sohn AG & Co. KG have consistently demonstrated excellence in clinical research and development. Emerging innovators including DeepCure and Eisai Co., Ltd. are also making significant inroads with specialized treatment offerings. Industry giants like Eli Lilly and Company, F. Hoffmann-La Roche Ltd., and Fresenius Kabi AG continue to leverage extensive research networks to drive product innovation. In addition, organizations such as Galapagos NV, Gilead Sciences, Inc., GlaxoSmithKline PLC, and ILTOO Pharma SAS provide crucial insights into market strategies and emerging trends. Well-established names including Johnson & Johnson Services Inc., medac GmbH, Merck & Co., Inc., and Novartis AG underscore the market's competitive intensity. Not to be overlooked are companies like Otter Pharmaceuticals, LLC by Assertio Holdings, Inc., Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sanofi SA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB S.A., and Vertex Pharmaceuticals Incorporated, whose collaborative efforts continue to redefine therapeutic standards in the field. Their strategic initiatives not only drive competitive advancements but also significantly impact the overall market dynamics.

The report delves into recent significant developments in the Anti-Rheumatics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alvotech, Amgen Inc., ANI Pharmaceuticals, Inc., AstraZeneca PLC, Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, C. H. Boehringer Sohn AG & Co. KG, DeepCure, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Fresenius Kabi AG, Galapagos NV, Gilead Sciences, Inc., GlaxoSmithKline PLC, ILTOO Pharma SAS, Johnson & Johnson Services Inc., medac GmbH, Merck & Co., Inc., Novartis AG, Otter Pharmaceuticals, LLC by Assertio Holdings, Inc., Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sanofi SA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB S.A., and Vertex Pharmaceuticals Incorporated. Actionable Recommendations for Strategic Market Leadership

Industry leaders are encouraged to adopt a multifaceted approach to harness the full potential of the anti-rheumatics market. To remain competitive, it is essential to invest in robust R&D capabilities that focus on precision medicine and personalized therapies, ensuring that treatment options are tailored to individual patient needs. Expanding product portfolios across diverse drug classes and routes of administration can effectively address varying patient demographics and preferences. Leaders should also explore strategic partnerships and collaborations to accelerate innovation and expand market access, particularly in emerging economies where healthcare infrastructure is rapidly evolving. An emphasis on data-driven insights will enable decision-makers to identify untapped market segments and optimize distribution channels, including hospital, online, and retail pharmacies. Furthermore, leveraging digital technologies such as AI and machine learning can streamline clinical trials and enhance patient engagement. Regulatory compliance must remain at the forefront of any strategic initiative, with a proactive approach to meet evolving global standards. By embracing these recommendations, companies can not only mitigate market risks but also capitalize on emerging trends, ultimately driving sustainable growth and competitive differentiation in a constantly evolving healthcare landscape.

Conclusion: Synthesizing Insights for Future Growth

In summary, the anti-rheumatics market presents robust opportunities underpinned by transformative technological and regulatory advancements. The in-depth segmentation analysis, regional evaluations, and company performance insights collectively reinforce a narrative of dynamic growth and innovation. As the landscape continues to evolve with a focus on targeted therapies and patient-centric solutions, stakeholders are well-positioned to benefit from these changes by strategically aligning their business models with current market trends. This comprehensive summary encapsulates the critical areas that require focus and continued investment to ensure long-term success in the anti-rheumatics domain.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increase in the prevalence of rheumatic disorders
    • 5.1.1.2. Rise in awareness related to early screening and treatment of rheumatoid arthritis
    • 5.1.1.3. Growing emphasis on precision therapeutics and personalized medicine
  • 5.1.2. Restraints
    • 5.1.2.1. Side effects and safety issues associated with anti-rheumatic drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Government initiatives and support for the research and development of the rheumatic diseases
    • 5.1.3.2. Significant development and marketing of cost-effective biosimilars
  • 5.1.4. Challenges
    • 5.1.4.1. Complex drug development and approval processes
• 5.2. Market Segmentation Analysis
  • 5.2.1. Drug Class: Increasing adoption of nonsteroidal anti-inflammatory drugs due to their accessibility, affordability, and effective management of pain
  • 5.2.2. Route Of Administration: Advancements in oral drug formulations aiming to improve bioavailability and minimize adverse effects
  • 5.2.3. Type: Significant preference for prescription-based drugs in managing severe and chronic rheumatic diseases
  • 5.2.4. Disease Type: Evolving personalized medicine advancement in rheumatoid arthritis to optimize treatment outcomes and minimize side effects.
  • 5.2.5. Distribution Channel: Expanding online pharmacies for anti-rheumatic medication distribution
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Anti-Rheumatics Market, by Drug Class

• 6.1. Introduction
• 6.2. Corticosteroids
• 6.3. Disease Modifying Anti-rheumatics Drugs
  • 6.3.1. Biologic DMARDs
    • 6.3.1.1. B-cell Inhibitors
    • 6.3.1.2. Interleukin Inhibitors
    • 6.3.1.3. T-cell Co-stimulation Modulators
    • 6.3.1.4. Tumor Necrosis Factor (TNF) Inhibitors
  • 6.3.2. Conventional DMARDs
  • 6.3.3. Targeted Synthetic DMARDs
• 6.4. Nonsteroidal Anti-inflammatory Drugs
• 6.5. Uric Acid Drugs

7. Anti-Rheumatics Market, by Route Of Administration

• 7.1. Introduction
• 7.2. Injectable
• 7.3. Oral
• 7.4. Topical

8. Anti-Rheumatics Market, by Type

• 8.1. Introduction
• 8.2. Over-the-Counter Drugs
• 8.3. Prescription-Based Drugs

9. Anti-Rheumatics Market, by Disease Type

• 9.1. Introduction
• 9.2. Ankylosing Spondylitis
• 9.3. Bursitis
• 9.4. Gout
• 9.5. Juvenile Idiopathic Arthritis
• 9.6. Osteoarthritis
• 9.7. Osteoporosis
• 9.8. Polymyalgia Rheumatica
• 9.9. Psoriatic Arthritis
• 9.10. Rheumatoid Arthritis
• 9.11. Sjogren's Syndrome
• 9.12. Systemic Lupus Erythematosus
• 9.13. Systemic Sclerosis/Scleroderma
• 9.14. Tendinitis

10. Anti-Rheumatics Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Hospital Pharmacies
• 10.3. Online Pharmacies
• 10.4. Retail Pharmacies

11. Americas Anti-Rheumatics Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Anti-Rheumatics Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Anti-Rheumatics Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Johnson & Johnson showcases advances in rheumatic disease treatments with 43 abstracts at ACR 2024
  • 14.3.2. FDA expands Shorla's JYLAMVO approval to combat pediatric oncology and autoimmune conditions
  • 14.3.3. DeepCure's DC-9476 methotrexate resistance in rheumatoid arthritis treatment
  • 14.3.4. FDA approval of Kevzara for treatment of pediatric and adult inflammatory arthritis
  • 14.3.5. Eisai and nippon medac launch Japan's first self-administered methotrexate pen
  • 14.3.6. Teva and Alvotech introduce SIMLANDI an interchangeable Humira biosimilar in the U.S.
  • 14.3.7. Kiniksa advances abiprubart in Phase 2b Trial for Sjogren's Disease, building on results from rheumatoid arthritis trial
  • 14.3.8. Fresenius Kabi's FDA approval of TYENNE tocilizumab biosimilar introduces in the anti-rheumatics market
  • 14.3.9. FDA approval revolutionizes rheumatic care with Novartis' Cosentyx
  • 14.3.10. Sandoz launches citrate-free high-concentration biosimilar Hyrimoz in the U.S. market
• 14.4. Strategy Analysis & Recommendation
  • 14.4.1. GlaxoSmithKline PLC
  • 14.4.2. Johnson & Johnson Services Inc.
  • 14.4.3. Novartis AG
  • 14.4.4. AbbVie Inc.

Companies Mentioned

• 1. AbbVie Inc.
• 2. Alvotech
• 3. Amgen Inc.
• 4. ANI Pharmaceuticals, Inc.
• 5. AstraZeneca PLC
• 6. Bayer AG
• 7. Biogen Inc.
• 8. Bristol-Myers Squibb Company
• 9. C. H. Boehringer Sohn AG & Co. KG
• 10. DeepCure
• 11. Eisai Co., Ltd.
• 12. Eli Lilly and Company
• 13. F. Hoffmann-La Roche Ltd.
• 14. Fresenius Kabi AG
• 15. Galapagos NV
• 16. Gilead Sciences, Inc.
• 17. GlaxoSmithKline PLC
• 18. ILTOO Pharma SAS
• 19. Johnson & Johnson Services Inc.
• 20. medac GmbH
• 21. Merck & Co., Inc.
• 22. Novartis AG
• 23. Otter Pharmaceuticals, LLC by Assertio Holdings, Inc.
• 24. Pfizer, Inc.
• 25. Regeneron Pharmaceuticals, Inc.
• 26. Sanofi SA
• 27. Takeda Pharmaceutical Company Limited
• 28. Teva Pharmaceutical Industries Ltd.
• 29. UCB S.A.
• 30. Vertex Pharmaceuticals Incorporated